Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK.

× No keyword cloud information.

29 in total

1. Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy.

Authors: D Ross Camidge; Margaret Skokan; Porntip Kiatsimkul; Barbara Helfrich; Xian Lu; Anna E Barón; Nathan Schulte; DeLee Maxson; Dara L Aisner; Wilbur A Franklin; Robert C Doebele; Marileila Varella-Garcia
Journal: Cancer Date: 2013-09-10 Impact factor: 6.860

Review 2. [New development lines in immunology. Perspective of pathology].

Authors: J Rüschoff; D Zielinski; E Heinmöller
Journal: Pathologe Date: 2013-11 Impact factor: 1.011

Review 3. ALK alterations and inhibition in lung cancer.

Authors: Tri Le; David E Gerber
Journal: Semin Cancer Biol Date: 2016-09-13 Impact factor: 15.707

4. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.

Authors: Marina Pekar-Zlotin; Fred R Hirsch; Lior Soussan-Gutman; Maya Ilouze; Addie Dvir; Theresa Boyle; Murry Wynes; Vincent A Miller; Doron Lipson; Gary A Palmer; Siraj M Ali; Shlomi Dekel; Ronen Brenner; Paul A Bunn; Nir Peled
Journal: Oncologist Date: 2015-02-26

5. ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization.

Authors: Andrew S Williams; Wenda Greer; Drew Bethune; Kenneth J Craddock; Gordon Flowerdew; Zhaolin Xu
Journal: Virchows Arch Date: 2016-08-25 Impact factor: 4.064

Review 6. Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib.

Authors: Biagio Ricciuti; Andrea De Giglio; Carmen Mecca; Cataldo Arcuri; Sabrina Marini; Giulio Metro; Sara Baglivo; Angelo Sidoni; Guido Bellezza; Lucio Crinò; Rita Chiari
Journal: Med Oncol Date: 2018-04-17 Impact factor: 3.064

Review 7. Prognostic and predictive biomarkers in lung cancer. A review.

Authors: Erik Thunnissen; Kimberly van der Oord; Michael den Bakker
Journal: Virchows Arch Date: 2014-01-14 Impact factor: 4.064

8. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.

Authors: Ruoshi Shi; Marileila Varella-Garcia; Ming Li; Olga Ludkovski; Arnavaz Danesh; Christine Ng; Nhu-An Pham; Trevor Pugh; Frances A Shepherd; Ming-Sound Tsao
Journal: J Thorac Oncol Date: 2016-09-06 Impact factor: 15.609

9. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators.

Authors: Murry W Wynes; Lynette M Sholl; Manfred Dietel; Ed Schuuring; Ming S Tsao; Yasushi Yatabe; Raymond R Tubbs; Fred R Hirsch
Journal: J Thorac Oncol Date: 2014-05 Impact factor: 15.609

10. Quantitative Multiplexed Proteomics Could Assist Therapeutic Decision Making in Non-Small Cell Lung Cancer Patients with Ambiguous ALK Test Results.

Authors: Ho Jung An; Eunkyung An; Shahrooz Rabizadeh; Wei-Li Liao; Jon Burrows; Todd Hembrough; Jin Hyung Kang; Chan Kwon Park; Tae-Jung Kim
Journal: Cancers (Basel) Date: 2021-05-12 Impact factor: 6.639